Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in Infants with Down Syndrome
NCT04751136Phase 2Completed
- Sponsor
- Mansoura University Children Hospital
- Start
- Sep 2016
- Primary completion
- Feb 2019
- Modality
- Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cerebrolysin in Down syndrome (2 arms), sponsored by Mansoura University Children Hospital. Primary endpoint: Rate of neurocognitive development at 12 months. Started Sep 2016; status: completed.
02
Drugs
cerebrolysin
03
Conditions
Down syndrome
Beyond the preview
Go deeper on NCT04751136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751136.